Multicenter case-control study of association of statin and other antilipemic use with prostate cancer risk

Post hoc analysis of the population-based French multicenter EPICAP case-control study investigated the association of use of statins and other antilipemic drugs with risk of prostate cancer. The analysis included 819 incident prostate cancer cases and 879 controls frequency-matched by age. The use of overall antilipemic drugs was not associated with prostate cancer risk, whereas the use of statins (OR 0.52; 95% CI 0.27-1.00), particularly lipophilic statins (0.30; 0.12-0.77), was inversely associated with high-grade prostate cancer (ISUP score ≥ 4). When taking into account the duration of use, long duration (≥ 10 years) of statins and lipophilic statins was inversely associated with prostate cancer overall (OR 0.69; 95% CI 0.47-1.01 and 0.54; 0.35-0.85, respectively) and with high-grade prostate cancer (0.49; 0.24-1.01, and 0.26; 0.09-0.72, respectively). The authors conclude that these results suggest an inverse association between use of statins, particularly lipophilic statins, and risk of high-grade prostate cancer.